It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Inflammation-based prognostic indicators have been developed to predict the prognosis in patients with pancreatic cancer. However, prognostic indices have not been established in patients with unresectable pancreatic cancer, including those without indication for chemotherapy at diagnosis. This study aimed to identify the predictors in all patients with unresectable pancreatic cancer. We retrospectively analyzed data of 119 patients with unresectable pancreatic cancer from June 2006 to September 2018. The following laboratory parameters were evaluated: the Glasgow Prognostic Score (GPS), modified GPS, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein albumin (CRP/Alb) ratio, and prognostic nutritional index (PNI). We performed time-dependent receiver operating characteristic analysis, overall survival (OS) analysis, and univariate and multivariate analyses to determine the prognostic factors in patients with unresectable pancreatic cancer. The cut-off value for NLR was determined to be 3.74. The 6-month OS rates in low and high NLR groups were 75.5% and 18.8% (P < 0.001). In the univariate analysis, advanced age (P = 0.003), metastatic pancreatic cancer (P = 0.037), no treatment (P < 0.001), worse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) (P < 0.001), high GPS (P < 0.001), high modified GPS (P < 0.001), high NLR (P < 0.001), high PLR (P = 0.002), high CRP/Alb ratio (P < 0.001), and low PNI (P < 0.001) were identified as the prognostic factors. The multivariate analysis revealed that metastatic pancreatic cancer (P = 0.046), no treatment (P < 0.001), worse ECOG-PS (P = 0.002), and high NLR (P < 0.001) were independently associated with OS. We revealed that the high NLR could be an independent indicator of poor prognosis in patients with unresectable pancreatic cancer.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Fukuchiyama City Hospital, Department of Gastroenterology and Hepatology, Fukuchiyama-city, Japan; Kyoto Prefectural University of Medicine, Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto, Japan (GRID:grid.272458.e) (ISNI:0000 0001 0667 4960)
2 Fukuchiyama City Hospital, Department of Gastroenterology and Hepatology, Fukuchiyama-city, Japan (GRID:grid.272458.e)
3 Fukuchiyama City Hospital, Department of Gastroenterology and Hepatology, Fukuchiyama-city, Japan (GRID:grid.272458.e); Kyoto Prefectural University of Medicine, Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto, Japan (GRID:grid.272458.e) (ISNI:0000 0001 0667 4960)
4 Fukuchiyama City Hospital, Department of Medical Oncology, Fukuchiyama-city, Japan (GRID:grid.272458.e)
5 Kyoto Prefectural University of Medicine, Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto, Japan (GRID:grid.272458.e) (ISNI:0000 0001 0667 4960)